<code id='4A49B944DD'></code><style id='4A49B944DD'></style>
    • <acronym id='4A49B944DD'></acronym>
      <center id='4A49B944DD'><center id='4A49B944DD'><tfoot id='4A49B944DD'></tfoot></center><abbr id='4A49B944DD'><dir id='4A49B944DD'><tfoot id='4A49B944DD'></tfoot><noframes id='4A49B944DD'>

    • <optgroup id='4A49B944DD'><strike id='4A49B944DD'><sup id='4A49B944DD'></sup></strike><code id='4A49B944DD'></code></optgroup>
        1. <b id='4A49B944DD'><label id='4A49B944DD'><select id='4A49B944DD'><dt id='4A49B944DD'><span id='4A49B944DD'></span></dt></select></label></b><u id='4A49B944DD'></u>
          <i id='4A49B944DD'><strike id='4A49B944DD'><tt id='4A49B944DD'><pre id='4A49B944DD'></pre></tt></strike></i>

          leisure time

          leisure time

          author:explore    Page View:443
          Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT
          Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

          After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

          The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

          advertisement

          Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          ProMED sees offers of support, but its future remains unclear
          ProMED sees offers of support, but its future remains unclear

          ProMEDmapScreengrabviaProMEDWithitsfutureindoubt,ProMED,thefinanciallystrappedinfectiousdiseasessurv

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Eye stem cell transplant could help restore vision in injured people

          UlaJurkunas,associatedirectorofthecorneaserviceatMassEyeandEar,performsthefirstCALECsurgery.Courtesy